Zimmer Biomet Logo

PDF Download PDF    Print page    Email page    Add to Briefcase Add to briefcase
« Previous Release | Next Release »

Zimmer Launches Trilogy(R) Acetabular System Constrained Liner in U.S.

WARSAW, Ind., Mar 11, 2003 /PRNewswire-FirstCall via COMTEX/ --

Zimmer Holdings, Inc. (NYSE: ZMH) announced today that it has begun sales in the United States of the Trilogy(R) Acetabular System Constrained Liner. Zimmer recently received clearance from the Food and Drug Administration to begin sales of the product, which has been available in markets outside of the U.S. since 2001.

"The revision hip market is one of the fastest growing segments in orthopaedics, with procedure growth of nearly 15%, and this addition gives us a comprehensive offering for acetabular revision," said Ray Elliott, Chairman, President and CEO of Zimmer. "The Trilogy System is already well accepted among surgeons, but the addition of the constrained liner will make the line more attractive to both Zimmer and non-Zimmer customers."

Constrained liners are often used in revision surgeries to address situations where the hip has a tendency to dislocate. The extra constraint provided by the liner design helps keep the hip replacement components properly mated.

"Because the Trilogy Constrained Liner mates with other Trilogy components, surgeons now have the flexibility to leave a well-fixed acetabular shell in place during a revision surgery, and simply insert a new liner," said Michael J. Anderson, M.D., an orthopaedic surgeon with the Blount Orthopaedic Clinic in Milwaukee. "Revision procedures are typically much more complicated than the initial hip replacement, so it's important that surgeons have as many tools as possible to address each patient's revision needs. This will allow us to restore function in many patients who would otherwise be facing ongoing problems with dislocation."

Zimmer, based in Warsaw, Indiana, is a global leader in the design, development, manufacture and marketing of reconstructive orthopaedic implants and trauma products. Orthopaedic reconstruction implants restore joint function lost due to disease or trauma in joints such as knees, hips, shoulders and elbows. Trauma products are devices used primarily to reattach or stabilize damaged bone and tissue to support the body's natural healing process. Zimmer also manufactures and markets other products related to orthopaedic and general surgery. For the year 2002, Zimmer recorded worldwide revenues of approximately $1.4 billion. Zimmer was founded in 1927 and has more than 3,600 employees worldwide.

Visit Zimmer on the worldwide web at www.zimmer.com

This press release contains forward-looking statements based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management. Forward- looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. These risks and uncertainties include, but are not limited to, price and product competition, rapid technological development, demographic changes, dependence on new product development, the mix of our products and services, customer demand for our products and services, our ability to successfully integrate acquired companies, control of costs and expenses, our ability to form and implement alliances, international growth, U.S. and foreign government regulation, reimbursement levels from third-party payors, general industry and market conditions and growth rates and general domestic and international economic conditions including interest rate and currency exchange rate fluctuations. For a further list and description of such risks and uncertainties, see the reports filed by Zimmer with the Securities and Exchange Commission. Zimmer disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Zimmer Holdings, Inc.

Media, Brad Bishop, Public Affairs, +1-574-372-4291, or
bradley.bishop@zimmer.com, or Investors, Sam Leno, Chief Financial Officer,
+1-574-372-4790, or sam.leno@zimmer.com, both of Zimmer

Copyright (C) 2003 PR Newswire. All rights reserved.

News Provided by COMTEX

Close window | Back to top